Medtronic receives approval to update Resolute Integrity DAPT labelling

141

Medtronic has announced that it has approval to update the CE mark dual antiplatelet therapy (DAPT) labelling for its drug-eluting Resolute Integrity stent, meaning that DAPT can be discontinued or interrupted after one month.

According to a company press release, one month discontinuation or interruption of DAPT is the shortest minimum duration referenced on the label for any device of its kind.


The press release added that the updated labelling stated: “One year data from the RESOLUTE clinical programme indicates low stent thrombosis rates for those who interrupted or discontinued DAPT any time after one month. While physicians should continue to adhere to current ESC or ACC/AHA/SCAI guidelines for percutaneous coronary intervention, patients who interrupt or discontinue DAPT medication one month or more after stent implantation are considered at low risk and showed no increased risk for stent thrombosis.”


At present, DAPT guidelines for patients who receive a drug-eluting stent differ by geographic region, but generally recommend daily compliance for six to 12 months. For a variety of reasons, however, some patients interrupt or discontinue their DAPT early, which raises safety concerns.


“An independent analysis of data on nearly 5,000 patients from the global RESOLUTE clinical programme who received a Resolute drug-eluting stent shows that the greatest risk of stent thrombosis due to DAPT interruption is within the first 30 days of the implant procedure,” explained Sigmund Silber, director of the Heart Centre at the Isar in Munich, Germany. “It also shows that DAPT interruption after 30 days is associated with a low risk of stent thrombosis and no increased risk for cardiac death or target vessel myocardial infarction.”


Silber, a member of the ESC 2010 guidelines committee for myocardial revascularisation, presented this analysis at TCT 2012, which took place in Miami in October. Ajay Kirtane, an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center, plans to present additional analysis during ACC.13, which is scheduled to take place in San Francisco from March 9–11.


This labelling update applies to product distributed in countries that accept the CE mark. It does not apply to product distributed beyond these countries, including the USA

 

(Visited 25 times, 1 visits today)